The anti-factor Xa range for low molecular weight heparin thromboprophylaxis

Salena May Ward, Matthew Yuankun Wei

Research output: Contribution to journalArticleOtherpeer-review

32 Citations (Scopus)


Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying
the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.
Original languageEnglish
Article number5844
Pages (from-to)80-83
Number of pages4
JournalHematology Reports
Issue number4
Publication statusPublished - 23 Nov 2015

Cite this